Tuberk et al. found that complement components (C3 and C4) levels were abnormally expressed in lung cancer patients with multiple cell types compared to that in control group, and aberrant C3 or C4 could function as a prognostic biomarker for patients with lung cancer 26. Here, C4A is linked to lung cancer.